## In The Supreme Court of the United States

No. 18-692

MYLAN PHARMACEUTICALS INC., MYLAN INC.,
ALEMBIC PHARMACEUTICALS LTD., SUN PHARMA GLOBAL FZE,
SUN PHARMACEUTICAL INDUSTRIES, LTD.,
Petitioners,

v.

UCB, INC., UCB BIOPHARMA SPRL, RESEARCH CORPORATION TECHNOLOGIES, INC., HARRIS FRC CORPORATION, Respondents.

## AFFIDAVIT OF COMPLIANCE

This Amicus Brief on Behalf of Association for Accessible Medicine in Support of the Petition has been prepared using:

Microsoft Word 2016;

Century Schoolbook;

12-Point Type Space.

As required by Supreme Court Rule 33.1(h), I certify that the Amicus Brief contains 5,960 words, excluding the parts of the brief that are exempted by Supreme Court Rule 33.1(d).

I declare under penalty of perjury that the foregoing is true and correct.

Affiant, Kelly A. Reese

THE LEX GROUPDC

1050 Connecticut Avenue, N.W.

Suite 500, #5190

Washington, D.C. 20036

(202) 955-0001

I am duly authorized under the laws of the District of Columbia to administer oaths.

Notary Public

District of Columbia: SS

Subscribed and Sworn to before me, in my presence,

this 27th day of DECEMBER, 2018

Notary Public, D.C.

My commission expires \_

My Commission Expires:

To be filed on behalf of counsel for Amicus Curiae:

Jeffrey K. Francer ASSOCIATION FOR ACCESSIBLE MEDICINES 601 New Jersey Ave., N.W., Suite 850 Washington, D.C. 20001 Richard J. Hoskins
Counsel of Record
Imron T. Aly
Joel M. Wallace
SCHIFF HARDIN LLP
233 S Wacker Drive, Suite 7100
Chicago, IL 60606
(312) 258-5509
rhoskins@schiffhardin.com

Dated: December 27, 2018

